公开(公告)号：US06407075B1

公开(公告)日：2002-06-18

申请号：US09254286

申请日：1999-07-06

Applicant: Catherine A. Scott ,  David F. Horrobin

Inventor： Catherine A. Scott ,  David F. Horrobin

IPC: A61K3170

CPC classification number: A61K31/201 ,  A61K31/202

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract translation: 制备用于治疗和预防分子中具有14至26个碳链长度并具有2-6个双键的多不饱和脂肪酸的抗癌化疗副反应的药物用于顺式或反式构型，以及 这种治疗或预​​防的方法，其中所述脂肪酸用作活性物质。

公开(公告)号：US5583159A

公开(公告)日：1996-12-10

申请号：US408135

申请日：1995-03-21

Applicant: David F. Horrobin ,  Catherine A. Scott

Inventor： David F. Horrobin ,  Catherine A. Scott

IPC: A61K31/20 ,  A61K31/202 ,  A61P25/00 ,  A61P43/00

CPC classification number: A61K31/202 ,  A61K31/20

Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract translation: 通过施用GLA和/或DGLA来防止或治疗由于暴露于电离辐射而对内部组织，特别是对中枢神经系统的损伤。 含有GLA和/或DGLA用于治疗或预防的药物还可以进一步包含EPA和/或DHA。

公开(公告)号：US5508307A

公开(公告)日：1996-04-16

申请号：US378708

申请日：1995-01-26

Applicant: David F. Horrobin ,  Catherine A. Scott

Inventor： David F. Horrobin ,  Catherine A. Scott

IPC: A61K31/20 ,  A61K20060101 ,  A61K9/08 ,  A61K31/201 ,  A61K31/202 ,  A61K31/203 ,  A61K33/00

CPC classification number: A61K31/20

Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.

Abstract translation: 脂肪酸的安全静脉内给药方法，特别是n-6和n-3系列必需脂肪酸和共轭脂肪酸，其中脂肪酸或其一部分以锂的形式施用 盐，并且由此定期监测血浆锂水平以避免溶血，优选在长期内保持锂水平不高于0.7毫摩尔，优选在第一24-48小时内不超过0.4-0.5毫摩尔，或者仅在 一部分脂肪酸以锂盐的形式施用，相应比例的水平。

公开(公告)号：US5663202A

公开(公告)日：1997-09-02

申请号：US690545

申请日：1996-07-31

Applicant: David F. Horrobin ,  Catherine A. Scott

Inventor： David F. Horrobin ,  Catherine A. Scott

IPC: A61K31/20 ,  A61K31/202 ,  A61P25/00 ,  A61P43/00

CPC classification number: A61K31/202 ,  A61K31/20

Abstract: Damage to the gastrointestinal tract as a consequence of exposure to ionising radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract translation: 由于暴露于电离辐射而导致的胃肠道损伤通过施用GLA和/或DGLA来预防或治疗。 含有GLA和/或DGLA用于治疗或预防的药物还可以进一步包含EPA和/或DHA。

公开(公告)号：US06630157B1

公开(公告)日：2003-10-07

申请号：US09463300

申请日：2000-08-15

Applicant: David F. Horrobin ,  Hans-Jurgen Tritschler

Inventor： David F. Horrobin ,  Hans-Jurgen Tritschler

IPC: A61K4700

CPC classification number: A61K31/202 ,  A61K31/385 ,  Y10S514/866 ,  A61K31/20 ,  A61K2300/00

Abstract: Compostions of GLA and/or other EFAs with TA or related compounds, and their use in therapy or nutrition or in preparation of composition for therapy or nutrition, especially to improve cell membrane EFA concentration and/or (particularly in diabetic complications) impaired nerve function and blood flow.

Abstract translation: GLA和/或其他具有TA或相关化合物的EFAs的组合及其在治疗或营养中的用途或用于治疗或营养的组合物的用途，特别是改善细胞膜EFA浓度和/或（特别是在糖尿病并发症中）损害神经功能 和血流。

公开(公告)号：US5670540A

公开(公告)日：1997-09-23

申请号：US440987

申请日：1995-05-15

Applicant: David F. Horrobin ,  Philip Knowles ,  Mehar Singh Manku ,  Austin McMordie

Inventor： David F. Horrobin ,  Philip Knowles ,  Mehar Singh Manku ,  Austin McMordie

IPC: A23D9/00 ,  A23L1/30 ,  A61K8/11 ,  A61K8/30 ,  A61K8/37 ,  A61K31/23 ,  A61K31/232 ,  A61P17/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/08 ,  C07C69/52 ,  C07C69/587 ,  C11C3/00 ,  A61K31/22

CPC classification number: A61K31/232 ,  A23L33/12 ,  A61K31/23 ,  C07C69/52 ,  C07C69/587

Abstract: A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from gamma-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acide is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

Abstract translation: 用于治疗或作为营养补充剂的甘油三酸酯或含有甘油三酯的组合物，其中所述甘油三酯包含选自γ-亚麻酸和从其天然衍生的n-6EPAs的脂肪酸和十八碳四烯酸和n-3EFA 由甘油形成三酯，或者形成双酯，其中另一种酯化酰亚胺是亚油酸的单一残基，条件是如果选择的话，可以使用二元聚乙烯酰基单亚油酰甘油酯作为制剂 含有20重量％以上。

公开(公告)号：US5618558A

公开(公告)日：1997-04-08

申请号：US106989

申请日：1993-08-16

Applicant: David F. Horrobin ,  Brenda E. Reynolds

Inventor： David F. Horrobin ,  Brenda E. Reynolds

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/23 ,  A61P3/00 ,  A61P3/14 ,  A61P19/10 ,  A61P43/00 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/20

Abstract: Increasing gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptabe form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in treatment of osteoporosis.

Abstract translation: 通过施用GLA，DGLA或LA本身或以盐或其他药理学接受形式增加人或动物中的肠钙吸收，任选地与EPA，DHA或其他类似形式的EFA相关联，特别可用于治疗骨质疏松症。

公开(公告)号：US5594031A

公开(公告)日：1997-01-14

申请号：US422614

申请日：1995-04-13

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A01N37/52 ,  A01N43/40 ,  A61K20060101 ,  A61K8/19 ,  A61K8/362 ,  A61K31/185 ,  A61K33/00 ,  A61K33/14 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q19/00 ,  C01D20060101 ,  C07D213/64 ,  C07D213/69 ,  C07D213/84 ,  C07D213/85 ,  C07F9/22 ,  C07F9/36 ,  C07F9/44

CPC classification number: A61K8/362 ,  A61K8/0229 ,  A61K8/19 ,  A61Q19/00 ,  A61Q19/001 ,  A61Q19/008 ,  A61Q5/006 ,  A61Q5/02 ,  Y10S514/864

Abstract: The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising a topically acceptable excipient and an effective amount of a lithium salt.

Abstract translation: 本发明涉及一种皮肤治疗方法，其包括局部施用于受脂溢性皮炎影响的皮肤的步骤，该组合物含有一种赋形剂和约1％至30％的锂离子，所述量足以减少所述 皮肤。 本发明还涉及一种皮肤治疗方法，其包括局部施用于受脂溢性皮炎影响的皮肤的步骤，所述组合物含有局部可接受的赋形剂和有效量的锂盐。

公开(公告)号：US5580556A

公开(公告)日：1996-12-03

申请号：US367819

申请日：1995-01-03

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K38/21

CPC classification number: A61K31/20 ,  A61K38/21

Abstract: The use of one or more of gamma-linolenic acid, dihomo-gamma-linolenic acid and arachidonic acid for the manufacture of a medicament for use in enhancement of the anti-viral, anti-cancer or anti-inflammatory effects of interferons; the medicament containing or being for use with a medicament containing one or more interferons when not solely for enhancement of the effect of endogenous interferons.

Abstract translation: 使用一种或多种γ-亚麻酸，二氢-γ-亚麻酸和花生四烯酸来制造用于增强干扰素抗病毒，抗癌或抗炎作用的药物; 所述药物含有或用于含有一种或多种干扰素的药物，而不仅仅是为了增强内源性干扰素的作用。

公开(公告)号：US5516801A

公开(公告)日：1996-05-14

申请号：US365171

申请日：1994-12-28

Applicant: David F. Horrobin ,  Brenda E. Reynolds

Inventor： David F. Horrobin ,  Brenda E. Reynolds

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexaenoic acid (DHA) or docosapenmenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.

Abstract translation: 通过施用（i）GLA和/或其EFA代谢物，特别是快速产生的DGLA和/或（ii）EPA和/或其前体，十八碳四烯酸和20 ：4 n-3，以及代谢物，二十二碳六烯酸（DHA）或二十二碳二烯酸（22：5 n-3），或盐或其他药理学上可接受的形式。 这特别适用于预防或治疗肾钙质沉着症和/或肾结石。